{"id":483028,"date":"2021-04-28T07:03:19","date_gmt":"2021-04-28T11:03:19","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/alpha-9-theranostics-announces-11-million-series-a-financing-to-advance-portfolio-of-radiotherapeutics-and-diagnostics\/"},"modified":"2021-04-28T07:03:19","modified_gmt":"2021-04-28T11:03:19","slug":"alpha-9-theranostics-announces-11-million-series-a-financing-to-advance-portfolio-of-radiotherapeutics-and-diagnostics","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/alpha-9-theranostics-announces-11-million-series-a-financing-to-advance-portfolio-of-radiotherapeutics-and-diagnostics\/","title":{"rendered":"Alpha-9 Theranostics Announces $11 Million Series A Financing to Advance Portfolio of Radiotherapeutics and Diagnostics"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">VANCOUVER, British Columbia, April  28, 2021  (GLOBE NEWSWIRE) &#8212; Alpha-9 Theranostics Inc. announced today an $11 million Series A financing to advance a portfolio of novel radiotherapeutics and diagnostics. Longitude Capital led the financing with participation from BVF Partners L.P. and insiders. &#8220;We are delighted that Longitude and BVF are investing in Alpha-9,\u201d said Simon Pimstone, MD, PhD, Chairman of the Board of Directors. &#8220;These high-quality investors share our conviction in the promise of radiotherapeutics and diagnostics.\u201d David Hirsch, MD, PhD of Longitude Capital remarked, &#8220;Alpha9\u00a0is an exciting company, founded by leaders in the field, with a growing portfolio of novel assets. We believe that radiotherapeutics have the potential\u00a0to deliver on the promise of precision oncology and we look forward to working with the Alpha-9 team to advance multiple programs into clinical trials.\u201d<\/p>\n<p align=\"justify\">\n        <strong>About Alpha-9<\/strong>\n      <\/p>\n<p align=\"justify\">Alpha-9 Theranostics is a clinical stage, radiopharmaceutical company developing imaging and therapeutic molecules for solid and hematologic malignancies. Using proprietary technology and the Company\u2019s expertise, these differentiated molecules have the potential to meaningfully extend patients\u2019 lives with favorable safety profiles. Alpha-9 was founded by researchers from the University of British Columbia and BC Cancer, with the goal of improving the lives of patients affected by metastatic cancers. For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ZtnY2uGzoQh53ScAJ4Y1kCpX5tEsQWxwOzMBuzCv5aFyMZvdS8lvfISkTaoc3y-t-WcjuttKuZYWhtS7eoXF8w==\" rel=\"nofollow noopener\" target=\"_blank\">www.alpha9tx.com<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>About Longitude Capital<\/strong>\n      <\/p>\n<p align=\"justify\">Longitude Capital is a leading healthcare venture capital firm that invests in transformative biotechnology, medical technology and health solutions companies seeking to improve clinical outcomes, enhance quality of life, and drive efficiency of healthcare delivery. Founded in 2006, Longitude Capital invests in both privately held and publicly traded companies through a variety of investment approaches. Longitude Capital has offices in Menlo Park, CA, Greenwich, CT, and Boston, MA. For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=QXN_3ynar3PFiqY3uLXvOo5JviSrJjZku1JepgRpHOSAMMz09Jvoahm-sRZ6bzhfGKLLSDtrUoen0Kj2UPRFGhMdxigli1DZWAF9wZDd664=\" rel=\"nofollow noopener\" target=\"_blank\">www.longitudecapital.com<\/a> or <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=JM7XK4TuIjAIXBjZxklIr3GrRYHAGkpci2GxOv1QZ2sryC0jLI1gnnDdE5j347XNUIjv5bOCI1MKHRFdkXFoRMP6i6BCfTUPPuNYhhWeyfg=\" rel=\"nofollow noopener\" target=\"_blank\">LinkedIn<\/a>.<\/p>\n<p align=\"justify\">Source: Alpha-9<\/p>\n<p align=\"justify\">Contact Information:<br \/>David Hirsch MD, PhD<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=jIE49UoQd56IPmzHjy2xuFlaYOEvzZLid2l-8cs_pH9dFPjMedcENL5iftb-X22JuGsM21G_SUlvGpVIZJAXCA==\" rel=\"nofollow noopener\" target=\"_blank\">info@alpha9tx.com<\/a><\/p>\n<p>\u00a0<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyNTI0OCM0MTQzNDkzIzUwMDA3OTY5NA==\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/4fae300c-6581-4481-856f-2bc57b145c9f\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>VANCOUVER, British Columbia, April 28, 2021 (GLOBE NEWSWIRE) &#8212; Alpha-9 Theranostics Inc. announced today an $11 million Series A financing to advance a portfolio of novel radiotherapeutics and diagnostics. Longitude Capital led the financing with participation from BVF Partners L.P. and insiders. &#8220;We are delighted that Longitude and BVF are investing in Alpha-9,\u201d said Simon Pimstone, MD, PhD, Chairman of the Board of Directors. &#8220;These high-quality investors share our conviction in the promise of radiotherapeutics and diagnostics.\u201d David Hirsch, MD, PhD of Longitude Capital remarked, &#8220;Alpha9\u00a0is an exciting company, founded by leaders in the field, with a growing portfolio of novel assets. We believe that radiotherapeutics have the potential\u00a0to deliver on the promise of precision oncology and we look forward &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/alpha-9-theranostics-announces-11-million-series-a-financing-to-advance-portfolio-of-radiotherapeutics-and-diagnostics\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Alpha-9 Theranostics Announces $11 Million Series A Financing to Advance Portfolio of Radiotherapeutics and Diagnostics&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-483028","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Alpha-9 Theranostics Announces $11 Million Series A Financing to Advance Portfolio of Radiotherapeutics and Diagnostics - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/alpha-9-theranostics-announces-11-million-series-a-financing-to-advance-portfolio-of-radiotherapeutics-and-diagnostics\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Alpha-9 Theranostics Announces $11 Million Series A Financing to Advance Portfolio of Radiotherapeutics and Diagnostics - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"VANCOUVER, British Columbia, April 28, 2021 (GLOBE NEWSWIRE) &#8212; Alpha-9 Theranostics Inc. announced today an $11 million Series A financing to advance a portfolio of novel radiotherapeutics and diagnostics. Longitude Capital led the financing with participation from BVF Partners L.P. and insiders. &#8220;We are delighted that Longitude and BVF are investing in Alpha-9,\u201d said Simon Pimstone, MD, PhD, Chairman of the Board of Directors. &#8220;These high-quality investors share our conviction in the promise of radiotherapeutics and diagnostics.\u201d David Hirsch, MD, PhD of Longitude Capital remarked, &#8220;Alpha9\u00a0is an exciting company, founded by leaders in the field, with a growing portfolio of novel assets. We believe that radiotherapeutics have the potential\u00a0to deliver on the promise of precision oncology and we look forward &hellip; Continue reading &quot;Alpha-9 Theranostics Announces $11 Million Series A Financing to Advance Portfolio of Radiotherapeutics and Diagnostics&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/alpha-9-theranostics-announces-11-million-series-a-financing-to-advance-portfolio-of-radiotherapeutics-and-diagnostics\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-04-28T11:03:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyNTI0OCM0MTQzNDkzIzUwMDA3OTY5NA==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alpha-9-theranostics-announces-11-million-series-a-financing-to-advance-portfolio-of-radiotherapeutics-and-diagnostics\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alpha-9-theranostics-announces-11-million-series-a-financing-to-advance-portfolio-of-radiotherapeutics-and-diagnostics\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Alpha-9 Theranostics Announces $11 Million Series A Financing to Advance Portfolio of Radiotherapeutics and Diagnostics\",\"datePublished\":\"2021-04-28T11:03:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alpha-9-theranostics-announces-11-million-series-a-financing-to-advance-portfolio-of-radiotherapeutics-and-diagnostics\\\/\"},\"wordCount\":318,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alpha-9-theranostics-announces-11-million-series-a-financing-to-advance-portfolio-of-radiotherapeutics-and-diagnostics\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIyNTI0OCM0MTQzNDkzIzUwMDA3OTY5NA==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alpha-9-theranostics-announces-11-million-series-a-financing-to-advance-portfolio-of-radiotherapeutics-and-diagnostics\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alpha-9-theranostics-announces-11-million-series-a-financing-to-advance-portfolio-of-radiotherapeutics-and-diagnostics\\\/\",\"name\":\"Alpha-9 Theranostics Announces $11 Million Series A Financing to Advance Portfolio of Radiotherapeutics and Diagnostics - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alpha-9-theranostics-announces-11-million-series-a-financing-to-advance-portfolio-of-radiotherapeutics-and-diagnostics\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alpha-9-theranostics-announces-11-million-series-a-financing-to-advance-portfolio-of-radiotherapeutics-and-diagnostics\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIyNTI0OCM0MTQzNDkzIzUwMDA3OTY5NA==\",\"datePublished\":\"2021-04-28T11:03:19+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alpha-9-theranostics-announces-11-million-series-a-financing-to-advance-portfolio-of-radiotherapeutics-and-diagnostics\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alpha-9-theranostics-announces-11-million-series-a-financing-to-advance-portfolio-of-radiotherapeutics-and-diagnostics\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alpha-9-theranostics-announces-11-million-series-a-financing-to-advance-portfolio-of-radiotherapeutics-and-diagnostics\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIyNTI0OCM0MTQzNDkzIzUwMDA3OTY5NA==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIyNTI0OCM0MTQzNDkzIzUwMDA3OTY5NA==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alpha-9-theranostics-announces-11-million-series-a-financing-to-advance-portfolio-of-radiotherapeutics-and-diagnostics\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Alpha-9 Theranostics Announces $11 Million Series A Financing to Advance Portfolio of Radiotherapeutics and Diagnostics\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Alpha-9 Theranostics Announces $11 Million Series A Financing to Advance Portfolio of Radiotherapeutics and Diagnostics - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/alpha-9-theranostics-announces-11-million-series-a-financing-to-advance-portfolio-of-radiotherapeutics-and-diagnostics\/","og_locale":"en_US","og_type":"article","og_title":"Alpha-9 Theranostics Announces $11 Million Series A Financing to Advance Portfolio of Radiotherapeutics and Diagnostics - Market Newsdesk","og_description":"VANCOUVER, British Columbia, April 28, 2021 (GLOBE NEWSWIRE) &#8212; Alpha-9 Theranostics Inc. announced today an $11 million Series A financing to advance a portfolio of novel radiotherapeutics and diagnostics. Longitude Capital led the financing with participation from BVF Partners L.P. and insiders. &#8220;We are delighted that Longitude and BVF are investing in Alpha-9,\u201d said Simon Pimstone, MD, PhD, Chairman of the Board of Directors. &#8220;These high-quality investors share our conviction in the promise of radiotherapeutics and diagnostics.\u201d David Hirsch, MD, PhD of Longitude Capital remarked, &#8220;Alpha9\u00a0is an exciting company, founded by leaders in the field, with a growing portfolio of novel assets. We believe that radiotherapeutics have the potential\u00a0to deliver on the promise of precision oncology and we look forward &hellip; Continue reading \"Alpha-9 Theranostics Announces $11 Million Series A Financing to Advance Portfolio of Radiotherapeutics and Diagnostics\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/alpha-9-theranostics-announces-11-million-series-a-financing-to-advance-portfolio-of-radiotherapeutics-and-diagnostics\/","og_site_name":"Market Newsdesk","article_published_time":"2021-04-28T11:03:19+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyNTI0OCM0MTQzNDkzIzUwMDA3OTY5NA==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alpha-9-theranostics-announces-11-million-series-a-financing-to-advance-portfolio-of-radiotherapeutics-and-diagnostics\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alpha-9-theranostics-announces-11-million-series-a-financing-to-advance-portfolio-of-radiotherapeutics-and-diagnostics\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Alpha-9 Theranostics Announces $11 Million Series A Financing to Advance Portfolio of Radiotherapeutics and Diagnostics","datePublished":"2021-04-28T11:03:19+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alpha-9-theranostics-announces-11-million-series-a-financing-to-advance-portfolio-of-radiotherapeutics-and-diagnostics\/"},"wordCount":318,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alpha-9-theranostics-announces-11-million-series-a-financing-to-advance-portfolio-of-radiotherapeutics-and-diagnostics\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyNTI0OCM0MTQzNDkzIzUwMDA3OTY5NA==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alpha-9-theranostics-announces-11-million-series-a-financing-to-advance-portfolio-of-radiotherapeutics-and-diagnostics\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/alpha-9-theranostics-announces-11-million-series-a-financing-to-advance-portfolio-of-radiotherapeutics-and-diagnostics\/","name":"Alpha-9 Theranostics Announces $11 Million Series A Financing to Advance Portfolio of Radiotherapeutics and Diagnostics - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alpha-9-theranostics-announces-11-million-series-a-financing-to-advance-portfolio-of-radiotherapeutics-and-diagnostics\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alpha-9-theranostics-announces-11-million-series-a-financing-to-advance-portfolio-of-radiotherapeutics-and-diagnostics\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyNTI0OCM0MTQzNDkzIzUwMDA3OTY5NA==","datePublished":"2021-04-28T11:03:19+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alpha-9-theranostics-announces-11-million-series-a-financing-to-advance-portfolio-of-radiotherapeutics-and-diagnostics\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/alpha-9-theranostics-announces-11-million-series-a-financing-to-advance-portfolio-of-radiotherapeutics-and-diagnostics\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alpha-9-theranostics-announces-11-million-series-a-financing-to-advance-portfolio-of-radiotherapeutics-and-diagnostics\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyNTI0OCM0MTQzNDkzIzUwMDA3OTY5NA==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyNTI0OCM0MTQzNDkzIzUwMDA3OTY5NA=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alpha-9-theranostics-announces-11-million-series-a-financing-to-advance-portfolio-of-radiotherapeutics-and-diagnostics\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Alpha-9 Theranostics Announces $11 Million Series A Financing to Advance Portfolio of Radiotherapeutics and Diagnostics"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/483028","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=483028"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/483028\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=483028"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=483028"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=483028"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}